Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2025-07-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
安徽天禾律师事务所关于安徽安科生物工程（集团）股份有限公司第4期员工持股计划（草案）之法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the company's 4th employee stock ownership plan (员工持股计划). It extensively discusses the legal compliance, procedures, and regulatory adherence related to the employee stock ownership plan, referencing Chinese securities laws and regulatory guidelines. The document is not a financial report, earnings release, or management discussion, but a legal opinion on a specific corporate action. It is not a proxy solicitation or voting result announcement, but a legal compliance document. This fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories. The document length (7463 characters) and detailed legal content support this classification rather than a brief announcement or a full report like 10-K or IR.
2025-07-22 Chinese
安徽安科生物工程（集团）股份有限公司第4期员工持股计划管理办法
Regulatory Filings Classification · 95% confidence The document is titled as the "4th Employee Stock Ownership Plan Management Measures" of Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It is a detailed regulatory and procedural document outlining the rules, management, rights, obligations, and implementation procedures of an employee stock ownership plan. The content includes legal references, stock purchase prices, lock-up periods, management committee roles, and shareholder meeting procedures. It is not a financial report, earnings release, or announcement of voting results. It is a regulatory filing related to employee stock ownership plan management, which does not fit into other specific categories like Capital/Financing Update or Share Issue/Capital Change. Therefore, the best fitting category is Regulatory Filings (RNS), as it is a compliance and procedural document related to the employee stock ownership plan.
2025-07-10 Chinese
关于第八届董事会第二十次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 20th meeting of the 8th Board of Directors of Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It details approvals related to the company's 4th employee stock ownership plan and the authorization for the board to handle related matters. The document includes voting results and mentions that these matters will be submitted to the 2025 second extraordinary general meeting of shareholders. The content focuses on board decisions and governance matters rather than financial results or reports. The document length is 2475 characters, which is relatively short and consistent with a board/management announcement. There is no detailed financial data or comprehensive report content. Therefore, the document fits best under the category of Board/Management Information (MANG).
2025-07-10 Chinese
安徽安科生物工程（集团）股份有限公司第4期员工持股计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is titled as a "第4期员工持股计划（草案）摘要" which translates to "4th Employee Stock Ownership Plan (Draft) Summary". It is a detailed plan document describing the purpose, principles, participants, funding, stock source, pricing, duration, management, and other operational details of an employee stock ownership plan. It includes legal references, risk disclosures, management committee roles, and voting procedures related to the plan. The document is lengthy (15,000 characters) and contains substantive content about the employee stock ownership plan itself, not merely an announcement or summary of a report. It is not an annual or interim financial report, nor an earnings release, nor a regulatory filing or announcement. It is a detailed plan document related to capital structure and employee shareholding. According to the filing definitions, updates on company fundraising, financing activities, or capital structure changes fall under "Capital/Financing Update (CAP)". An employee stock ownership plan is a capital structure related financing and shareholding arrangement. Therefore, the document best fits the "Capital/Financing Update (CAP)" category.
2025-07-10 Chinese
董事会关于公司第4期员工持股计划草案合规性说明
Capital/Financing Update Classification · 95% confidence The document is a statement from the company's board regarding the compliance of the 4th employee stock ownership plan draft with relevant laws and regulations. It discusses the legality, procedural validity, and benefits of the employee stock ownership plan. There is no financial data, no report publication, no voting results, no management changes, no earnings or audit information. The document is a compliance explanation related to a capital/financing activity (employee stock ownership plan). Therefore, it fits best under Capital/Financing Update (CAP). The document length is short but contains substantive content about the stock plan compliance, not just an announcement or certification.
2025-07-10 Chinese
关于召开2025年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2025 second extraordinary general meeting of shareholders (临时股东大会) for Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It includes information about the meeting date, voting methods (onsite and online), registration details, agenda items for shareholder approval, and attachments such as proxy forms and voting procedures. The document does not contain financial statements or results but is an official announcement related to a shareholders' meeting. It is not a report itself but a notification about the meeting and voting process. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting procedures rather than the solicitation materials or voting results, it aligns best with Proxy Solicitation & Information Statement (PSI). The document length is 4185 characters, which is consistent with a detailed meeting notice and proxy materials. Hence, the classification is PSI with high confidence.
2025-07-10 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.